ACCRETAMAB
LIVE

Serial Number

77178675

Owner

KYOWA HAKKO KIRIN CO., LTD.

Attorney

Kaushal R. Odedra

Filing Date

May 11, 2007

Add to watchlist:

No watchlists yet
View on USPTO

ACCRETAMAB Trademark

Serial Number: 77178675 • Registration: 3653037

ACCRETAMAB is a trademark filed by KYOWA HAKKO KIRIN CO., LTD. on May 11, 2007. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

KYOWA HAKKO KIRIN CO., LTD. (58 trademarks)

1-6-1, OHTEMACHI, CHIYODA-KU
TOKYO , JP

Entity Type: 99

KYOWA HAKKO KOGYO CO., LTD. (51 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

KYOWA KIRIN CO., LTD. (47 trademarks)

TOKYO 100-0004 , JP

Entity Type: 03

Trademark Details

Filing Date

May 11, 2007

Registration Date

July 14, 2009

Published for Opposition

April 28, 2009

Goods & Services

Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals

[Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases]

Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 4, 2019 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Apr 10, 2019 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Apr 10, 2019 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Apr 10, 2019 89AG
TEAS SECTION 8 & 9 RECEIVED
Apr 8, 2019 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jul 14, 2018 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Aug 5, 2015 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Aug 5, 2015 8.PR
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 5, 2015 APRE
TEAS SECTION 8 RECEIVED
Jul 1, 2015 ES8R
REGISTERED-PRINCIPAL REGISTER
Jul 14, 2009 R.PR
PUBLISHED FOR OPPOSITION
Apr 28, 2009 PUBO
NOTICE OF PUBLICATION
Apr 8, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 23, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 23, 2009 CNSA
AMENDMENT FROM APPLICANT ENTERED
Feb 24, 2009 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2009 CRFA
PAPER RECEIVED
Feb 23, 2009 MAIL
INQUIRY AS TO SUSPENSION MAILED
Feb 10, 2009 CNSI
SUSPENSION INQUIRY WRITTEN
Feb 9, 2009 CNSI
AMENDMENT FROM APPLICANT ENTERED
Feb 9, 2009 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2009 CRFA
PAPER RECEIVED
Feb 6, 2009 MAIL
INQUIRY AS TO SUSPENSION MAILED
Jan 12, 2009 CNSI
SUSPENSION INQUIRY WRITTEN
Jan 11, 2009 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 11, 2008 RCCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 19, 2008 ASGN
LETTER OF SUSPENSION MAILED
Jun 11, 2008 CNSL
SUSPENSION LETTER WRITTEN
Jun 11, 2008 CNSL
AMENDMENT FROM APPLICANT ENTERED
Jun 10, 2008 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2008 CRFA
PAPER RECEIVED
Jun 9, 2008 MAIL
INQUIRY AS TO SUSPENSION MAILED
Mar 26, 2008 CNSI
SUSPENSION INQUIRY WRITTEN
Mar 25, 2008 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 24, 2008 RCCK
ASSIGNED TO LIE
Feb 24, 2008 ALIE
LETTER OF SUSPENSION MAILED
Aug 24, 2007 CNSL
SUSPENSION LETTER WRITTEN
Aug 24, 2007 CNSL
ASSIGNED TO EXAMINER
Aug 24, 2007 DOCK
NEW APPLICATION ENTERED
May 16, 2007 NWAP